NCT07024498 Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment
| NCT ID | NCT07024498 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, Davis |
| Condition | Opioid Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,492 participants |
| Start Date | 2025-11-01 |
| Primary Completion | 2028-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,492 participants in total. It began in 2025-11-01 with a primary completion date of 2028-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main purpose of this stepped wedge trial will be to test the impact of a bundle of implementation strategies designed to improve ED-outpatient care coordination on long-term buprenorphine retention among adult patients who start buprenorphine for opioid use disorder in a hospital emergency department (ED) and then are referred for continued outpatient buprenorphine treatment after they leave the ED. Our hypothesis is that adopting the bundle of implementation strategies will be associated with subsequent increases in: A) Cumulative number of days with active buprenorphine prescription at 3, 6, and 12 months after patients' initial ED visit (6 months = primary outcome) B) Proportion of patients with active buprenorphine prescriptions without gaps in buprenorphine coverage of more than 7 days at 3, 6, and 12 months after patients' initial ED visit C) Proportion of patients who fill at least 1 outpatient buprenorphine prescription within 30 days of their ED visit D) Clinician reported quality of ED-outpatient care coordination and care transitions
Eligibility Criteria
Inclusion Criteria: * patients who start buprenorphine for opioid use disorder at a participating ED
Contact & Investigator
Stephen G Henry, MD MSc
PRINCIPAL INVESTIGATOR
University of California, Davis
Frequently Asked Questions
Who can join the NCT07024498 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07024498 currently recruiting?
Yes, NCT07024498 is actively recruiting participants. Contact the research team at mkemiller@health.ucdavis.edu for enrollment information.
Where is the NCT07024498 trial being conducted?
This trial is being conducted at El Centro, United States, Irvine, United States, Placerville, United States, Sacramento, United States.
Who is sponsoring the NCT07024498 clinical trial?
NCT07024498 is sponsored by University of California, Davis. The principal investigator is Stephen G Henry, MD MSc at University of California, Davis. The trial plans to enroll 3,492 participants.